Related references
Note: Only part of the references are listed.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation
Robert Bentley et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case-control study
Huiting Chen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Abelacimab for Prevention of Venous Thromboembolism
Peter Verhamme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty The FOXTROT Randomized Clinical Trial
Jeffrey I. Weitz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis
Mayken Visser et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke
Jessica L. Rohmann et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex)
Blazej Glowicki et al.
CANADIAN JOURNAL OF CARDIOLOGY (2019)
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
Miklos Rohla et al.
BMJ OPEN (2019)
Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI
Benjamin Georgi et al.
STROKE (2019)
The prothrombotic state in atrial fibrillation: pathophysiological and management implications
Ahsan A. Khan et al.
CARDIOVASCULAR RESEARCH (2019)
Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis
Steven P. Grover et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries
Marco Proietti et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2018)
Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk JACC Review Topic of the Week
Paul M. Ridker
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps
Denis F. Noubouossie et al.
BLOOD (2017)
Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke
Piotr Kusak et al.
ARCHIVES OF MEDICAL SCIENCE (2016)
Association of Hemostatic Markers with Atrial Fibrillation: A Meta-Analysis and Meta-Regression
Na Wu et al.
PLOS ONE (2015)
Next Generation Antithrombotic Therapy: Focus on Antisense Therapy against Coagulation Factor XI
Giuseppe Lippi et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2015)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation
Suresh Krishnamoorthy et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients
Michal Zabczyk et al.
BLOOD COAGULATION & FIBRINOLYSIS (2012)
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
A. John Camm et al.
EUROPEAN HEART JOURNAL (2012)
Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients
Vanessa Roldan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events
Anetta Undas et al.
THROMBOSIS RESEARCH (2011)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
S. Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Cardiovascular complications of diabetes mellitus: The Tissue Factor perspective
Vladimir Y. Bogdanov et al.
THROMBOSIS RESEARCH (2010)
Factor XIa and tissue factor activity in patients with coronary artery disease
Saulius Butenas et al.
THROMBOSIS AND HAEMOSTASIS (2008)
Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation
Bethan Freestone et al.
CHEST (2007)
Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events
David T. Yang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Immunologic quantitation of tissue factors
B. Parhami-Seren et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
The function of factor XI in tissue factor-initiated thrombin generation
S Butenas et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
High levels of coagulation factor XI as a risk factor for venous thrombosis.
JCM Meijers et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
